繁體
简体中文
繁體中文

EDESA BIOTECH INC EDSA

等待開盤 08-22 09:30:00 美东时间

2.375

+0.019

+0.82%

华盛通華盛通
立即下載
  • 最 高2.44
  • 今 開2.40
  • 成交量 4298股
  • 最 低 2.375
  • 昨 收 2.3556
  • 總市值 1667.89万
  • 52周最高 5.00
  • 市盈率 --
  • 換手率 0.00%
  • 52周最低 1.55
  • 委 比 -33.33%
  • 總股本 702.27万
  • 歷史最高 133.70
  • 量 比 0.42
  • 振 幅 2.76%
  • 歷史最低 1.55
  • 每 手 1
  • 風險率 0.55%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Edesa Biotech Advances Vitiligo Treatment Amidst Steady Financial Performance

    Edesa Biotech ( ($EDSA) ) has provided an announcement. Edesa Biotech reported ...

    08-09 07:02

  • Edesa Biotech Q3 EPS $(0.25) Beats $(0.29) Estimate

    Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.29) by 13.79 percent. This is a 51.92 percent increase over losses of $(0.52) per share from the

    08-09 04:36

  • Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

    Edesa Biotech reported Q3 and Q9 2025 financial results, advancing manufacturing for its EB06 candidate in vitiligo with plans to submit IND data by end-2025. CEO Par Nijhawan highlighted EB06's favorable safety profile and potential benefits for patients with extensive vitiligo. Financially, operating expenses remained stable, with a slight decrease in R&D costs offset by increased EB06-related expenses. Net loss for Q3 and Q9 2025 was $1.7M and...

    08-08 20:35

  • 美股大行评级 | 潜在涨幅205.56%!康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元,维持"超配"评级

    <span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德:维持HIVE Digital Technologies(HIVE)"超配"评级,目标价从5美元升至5.5美元</p> <p>• BTIG:维持Theravance Biopharma(TBPH)"买入"评

    06-28 08:37

  • HC Wainwright & Co. Assumes Edesa Biotech at Buy, Announces Price Target of $5

    HC Wainwright &amp; Co. analyst Yi Chen assumes Edesa Biotech (NASDAQ:EDSA) with a Buy rating and announces Price Target of $5.

    06-27 23:24

  • 118倍的市盈率:资本市场如何让美国富裕起来

    文章讲述罗斯·佩罗的电子数据系统(EDS)1968年以118倍市盈率上市的传奇故事,及其展现的美国资本市场独特魅力。EDS在高风险下获得投资者热捧,首日收盘价比发行价高出40%,佩罗39岁成为美国首位科技亿万富翁。美国资本市场敢于承担风险的特性为科技初创企业提供了独特融资环境,培育出众多巨型公司。加密货币市场的兴起或将成为下一个冒险者和投资者汇聚的平台,推动新型资产的创新与繁荣。文章强调美国热情投资者不仅成就了企业家,也推动了国家经济的繁荣发展。

    05-28 06:41

  • Shein涉嫌违反欧盟产品安全法被升级调查

    (转自:首席商业新知官) 首席商业新知官:NO.1Business Review 欧盟监管风暴正以雷霆之势扑向快时尚巨头Shein。 根据彭博...

    05-27 18:22

  • Edesa Biotech Shifts Focus to Vitiligo Treatment in Q2 2025

    Edesa Biotech ( ($EDSA) ) has shared an announcement. Edesa Biotech reported it...

    05-15 05:23

  • Edesa Biotech Q2 EPS $(0.30) Misses $(0.29) Estimate

    Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.29) by 3.45 percent. This is a 48.28 percent increase over losses of $(0.58) per share from

    05-15 04:35